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The Influenza Complications Alert Network (FluCAN) 
is a sentinel hospital-based surveillance programme 
operating in all states and territories in Australia. 
We summarise the epidemiology of children hospital-
ised with laboratory-confirmed influenza in 2014 and 
reports on the effectiveness of inactivated trivalent 
inactivated vaccine (TIV) in children. In this observa-
tional study, cases were defined as children admit-
ted with acute respiratory illness (ARI) with influenza 
confirmed by PCR. Controls were hospitalised children 
with ARI testing negative for influenza. Vaccine effec-
tiveness (VE) was estimated as 1 minus the odds ratio 
of vaccination in influenza positive cases compared 
with test-negative controls using conditional logistic 
regression models. From April until October 2014, 402 
children were admitted with PCR-confirmed influenza. 
Of these, 28% were aged < 1 year, 16% were Indigenous, 
and 39% had underlying conditions predisposing to 
severe influenza. Influenza A was detected in 90% of 
cases of influenza; influenza A(H1N1)pdm09 was the 
most frequent subtype (109/141 of subtyped cases) 
followed by A(H3N2) (32/141). Only 15% of children 
with influenza received antiviral therapy. The adjusted 
VE of one or more doses of TIV for preventing hos-
pitalised influenza was estimated at 55.5% (95% 
confidence intervals (CI): 11.6–77.6%). Effectiveness 
against influenza A(H1N1)pdm09 was high (91.6% , 
95% CI: 36.0–98.9%) yet appeared poor against H3N2. 
In summary, the 2014 southern hemisphere TIV was 
moderately effective against severe influenza in chil-
dren. Significant VE was observed against influenza 
A(H1N1)pdm09.
Introduction
Influenza is a common respiratory viral infection that 
affects up to 5–10% of the population each year [1]. 
Previous studies demonstrate that young children 
have the highest rate of hospitalisation [2]. A national 
sentinel surveillance programme for severe influ-
enza was established in Australia in 2009, primarily 
to monitor hospitalisations in adults with confirmed 
influenza: the Influenza Complications Alert Network 
(FluCAN). Given the significant burden of disease in 
young children and the important role that children 
play in introducing and spreading influenza virus in the 
household and the community [3], paediatric influenza 
surveillance provides public health authorities with 
important and timely information on disease sever-
ity in the early phase of the winter respiratory virus 
season. Hospital-based sentinel surveillance enables 
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detailed information on the severity of illness to be 
collected, and complements community- and primary 
care-based surveillance systems. Comprehensive 
nationwide clinical data were collected from Australian 
children admitted to six tertiary paediatric hospitals 
during the pandemic in 2009 [4]. However, from 2010 
to 2013, insufficient numbers of children were pro-
spectively enrolled in existing surveillance programs 
to ascertain paediatric seasonal influenza activity and 
severity in Australia. Two tertiary paediatric hospitals 
(from the separate Paediatric Active Enhanced Disease 
Surveillance network (PAEDS) [5]) were included in the 
existing FluCAN sentinel system in 2014.
The Australian Technical Advisory Group on 
Immunisation (ATAGI) recommends influenza vaccina-
tion in all children 6 months and older, yet in 2014, 
influenza vaccine was only provided free of charge 
under the National Immunisation Programme (NIP) for 
children with comorbidities that predispose them to 
severe outcomes following influenza infection [6]. In 
Western Australia, a state funded programme has pro-
vided free influenza vaccine to all children between 6 
months and 5 years of age from 2008 [7-9]. Four brands 
of inactivated unadjuvanted trivalent influenza vac-
cine (TIV) were available for use in Australian children: 
more than 80% of vaccine administered to children 
in Australia was Vaxigrip or Vaxigrip junior (Sanofi-
Pasteur Pty Ltd; personal communication, Brynley Hull, 
October 2015). Live attenuated and quadrivalent influ-
enza vaccines were not available in Australia in 2014.
Previous studies have demonstrated that inactivated 
influenza vaccine is protective against influenza [10, 
11], yet have concluded that insufficient evidence 
exists to confirm the effectiveness in the very young. 
The Western Australian Influenza Vaccine Effectiveness 
(WAIVE) study has previously estimated vaccine effec-
tiveness (VE) of TIV in children aged 6 to 59 months 
attending a paediatric emergency department against 
any laboratory-confirmed influenza at 64.7% (95% 
confidence interval (CI): 33.7–81.2%) [7]. Insufficient 
numbers of hospitalised children have been enrolled 
in this and similar paediatric VE studies to generate 
robust estimates against hospitalisation. Cowling et al. 
estimated VE against hospitalisation with laboratory-
confirmed influenza to be 61.7% (95% CI: 43.0–74.2%) 
in Hong Kong (2009–2013) [12].
With nearly 70,000 notifications of laboratory-con-
firmed influenza, the incidence of disease in 2014 was 
high compared with previous seasons [13]. Virological 
surveillance of circulating strains suggested influenza 
A(H1N1)pdm09 predominated across most jurisdictions 
throughout the season, but influenza A(H3N2) was 
predominant in New South Wales and the Australian 
Capital Territory [14]. In this report, we describe the 
epidemiology of hospitalisation in children with con-
firmed influenza and report on VE estimates for the 
2014 southern hemisphere inactivated TIV.
Methods
FluCAN is a national hospital-based sentinel surveil-
lance system [15]. In 2014, surveillance was expanded 
to include two large specialty paediatric hospitals: 
Figure 1
Date of admission in children hospitalised with confirmed influenza, epidemiological cohort, Influenza Complications 

































Children’s Hospital at Westmead (New South Wales) 
and the Princess Margaret Hospital for Children 
(Western Australia). In addition, paediatric cases from 
the other 15 participating sites were also included: 
Canberra Hospital (ACT), University Hospital Geelong 
(VIC), Princess Alexandra Hospital (QLD), Cairns Base 
Hospital (QLD), and Alice Springs Hospital (NT) con-
tributed cases. Ethics approval has been obtained at 
all participating sites, at Monash University and the 
Australian National University.
An influenza case was defined as a paediatric patient 
(< 16 years) admitted to hospital with an acute respira-
tory illness (ARI) and with influenza confirmed by PCR. 
Influenza testing was initiated by clinicians based on 
clinical indications and local guidelines. All influenza 
cases were confirmed using real-time reverse tran-
scriptase PCR assays using standard primers. All tests 
were performed in local or referral laboratories accred-
ited by the National Association of Testing Authorities. 
An ARI was defined by the presence of new respiratory 
symptoms including cough and rhinorrhoea. A hospital 
admission was defined as requiring inpatient care out-
side of the emergency department.
Under FluCAN, surveillance is conducted during the 
southern hemisphere influenza season (i.e. April 
to October with follow up continuing to the end of 
November each year). Admission to an intensive care 
unit (ICU), including high dependency unit (HDU), was 
also recorded. The presence of risk factors predispos-
ing to severe outcomes following influenza infection 
including ethnicity (Indigenous or non-Indigenous 
Australian) and the presence of underlying conditions 
(hereafter referred to as comorbidities) was ascertained 
from the patient’s medical record [6]. Comorbidities 
assessed included congenital heart disease, chronic 
respiratory and neurological disorders, immunocom-
promising conditions or immunosuppression, Down 
syndrome and chronic illnesses such as diabetes mel-
litus and renal failure [6].
We examined factors associated with ICU admission 
and the length of hospital stay (LOS) using multivari-
able regression. Factors associated with ICU admission 
were determined using a logistic regression model, 
with factors retained in the multivariable model if 
p < 0.20. Factors associated with LOS were modelled 
using a linear regression, as the mean duration of stay 
was the parameter of interest. Standard errors were 
estimated using bootstrapping (1,000 replicates) to 
correct for heteroskedasticity.
Figure 2
Flowchart of children included in epidemiological and vaccine effectiveness cohorts, Influenza Complications Alert 
Network, Australia, April to October 2014 (n=747)
Influenza positive
(n = 402)
Excluded (n = 148)
• Age < 6 months (n = 66)
• Missing vaccination status (n = 54)
• Duration of symptoms > 7 days (n = 28)
Epidemiological cohort
VE analysis cohort
Excluded (n = 120)
• Age < 6 months (n = 80)
• Missing vaccination status (n = 34)













Estimation of vaccination coverage and 
effectiveness
Vaccination status was obtained from the medical 
record, by parental report and confirmed, in children < 7 
years of age, on the Australian Childhood Immunisation 
Register (ACIR). In those 10 years and older, ‘fully 
immunised’ was defined by receipt of one dose of 2014 
TIV more than 2 weeks before presentation. In children 
age < 10 years, ‘fully immunised’ was defined as either 
(i) two doses of TIV at least 21 days apart and at least 
2 weeks before presentation or (ii) one dose of TIV at 
least 2 weeks before presentation and receipt of at 
least one TIV dose in a previous year [6]. ‘Partially vac-
cinated’ children were those aged < 10 years receiving 
only one dose of vaccination in 2014 without receipt of 
TIV in previous years. ‘Unvaccinated’ children where 
those not receiving TIV in 2014 or receiving the vaccine 
less than 2 weeks before presentation.
Vaccination coverage was estimated in patients > 6 
months of age admitted with ARI who tested nega-
tive to influenza by PCR. We used an incidence density 
test negative design to estimate VE, where controls 
were selected from influenza-test negative subjects 
with ARI tested contemporaneously with a case: con-
trols could be test-negative for all pathogens or have 
an alternative pathogen detected [16-18]. VE was esti-
mated as 1 minus the odds ratio (OR) of vaccination in 
influenza-positive cases compared with test-negative 
control patients using methods previously described 
[15,19]. Only children > 6 months of age and tested 
within 7 days of admission were included in VE esti-
mates. A conditional logistic regression model using 
influenza case status as the dependent outcome was 
constructed from influenza vaccination and adjusted 
for potential confounders (age group < 2 years and 
comorbidities). The regression was stratified on site, 
except for the models that considered VE against H1N1 
due to small numbers. Models that included more age 
groups (< 1 year, 1–4 years, 5–9 years and ≥ 10 years,) 
and Indigenous status as adjusting variables were 
considered in sensitivity analyses. In addition, VE esti-
mates excluding children with duration of symptoms 
of > 7 days (as opposed to restriction the analysis to 
who underwent testing within 7 days) were performed. 
These adjustments had minimal effect (< 3%) on VE 
estimates and thus were dropped from the final model. 
Analyses were performed using Stata 13 for Windows 
(College Station, Texas, US).
Results
During the period 3 April to 31 October 2014, 402 chil-
dren were admitted with PCR-confirmed influenza to 
seven of 17 sentinel hospitals, including 283 admis-
sions to the two specialist paediatric hospitals, and 119 
admissions to five non-specialist hospitals (Table 1). 
The peak rate of admission was in late August (Figure 
1). Of these 402 children, 114 (28%) were < 1 year of age, 
63 (16%) were Indigenous Australians, and 155 (39%) 
had underlying comorbidities (Table 1; Table 2).
Table 1
Demographic characteristics of children hospitalised with confirmed influenza, epidemiological cohort, Influenza 
Complications Alert Network, Australia, April to October 2014 (n=402)
Influenza type Total influenza positive cases
A(H1N1A(H1N1)09pdm A(H3N2) A not subtyped B 
Number of children 109 32 218 42 402a
Age group
Neonate < 28 days 2 (1.8%) 0 (0.0%) 5 (2.3%) 0 (0.0%) 7 (1.7%)
Infant 28 days to 1 year 29 (26.6%) 9 (28.1%) 60 (27.5%) 8 (19.0%) 107 (26.6%)
1–5 years 40 (36.7%) 16 (50.0%) 94 (43.1%) 15 (35.7%) 165 (41.0%)
5–9 years 23 (21.1%) 5 (15.6%) 34 (15.6%) 12 (28.6%) 74 (18.4%)
10–16 years 15 (13.8%) 2 (6.3%) 25 (11.5%) 7 (16.7%) 49 (12.2%)
Male 62 (56.9%) 16 (50.0%) 107 (49.1%) 24 (57.1%) 209 (52.0%)
Indigenous 9 (8.3%) 3 (9.4%) 48 (22.0%) 3 (7.1%) 63 (15.7%)
Hospital
Alice Springs 0 (0.0%) 0 (0.0%) 43 (19.7%) 5 (11.9%) 48 (11.9%)
Canberra 15 (13.8%) 14 (43.8%) 0 (0.0%) 2 (4.8%) 31 (7.7%)
Cairns Base 4 (3.7%) 0 (0.0%) 10 (4.6%) 3 (7.1%) 17 (4.2%)
Children›s Hospital, 
Westmead 0 (0.0%) 0 (0.0%) 135 (61.9%) 16 (38.1%) 151 (37.6%)
Geelong Hospital 0 (0.0%) 0 (0.0%) 21 (9.6%) 0 (0.0%) 22 (5.5%)
Princess Alexandra 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.4%) 1 (0.2%)
Princess Margaret 90 (82.6%) 18 (56.3%) 9 (4.1%) 15 (35.7%) 132 (32.8%)
a One child with disease due to multiple subtypes included in total
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Presentation and treatment
In 395 patients with influenza where the duration of 
symptoms was known, the median duration of symp-
toms before admission was 3 days (interquartile range 
(IQR): 2, 5 days). Only 64 (15%) of patients with influ-
enza, received oseltamivir; of these, 24 patients were 
known to have received oseltamivir within 48 hours of 
symptom onset.
Admission to intensive care
Of all influenza cases, 40 (10%) were initially admitted 
to intensive care (ICU) and a further six (1%) patients 
were subsequently transferred to ICU after initial 
admission to a general ward. The presence of comor-
bidities was associated with intensive care admission: 
OR 2.80 (95% CI: 1.49–5.27, p = 0.001). Influenza B 
appeared associated with a lower risk of admission to 
ICU but this difference was not statistically significant: 
OR 0.36 (95% CI: 0.08–1.53, p = 0.16). In a multivariate 
model, only the presence of one or more comorbidity 
was associated with ICU admission (Table 3).
Outcome
The mean LOS of all patients was 3.7 days. The pres-
ence of comorbidities was associated with an increase 
in mean hospital length of stay of 2.6 days. Other fac-
tors associated with prolonged length of stay included 
ICU admission and being Indigenous but these dif-
ferences were not statistically significant (data not 
shown). The duration of hospital stay was similar in 
patients that received antivirals within 48 hours of 
symptom onset (median: 2.5 days; IQR: 2, 6 days), com-
pared with those who received antivirals more than 48 
hours after symptom onset (median: 4 days; IQR: 1, 
7 days) and who did not receive antivirals (median: 2 
days; IQR: 1, 3 days).
One in-hospital death was reported, in a 13-year-old 
boy with no known comorbidities.
Table 2
Risk factors, severity and outcomes in children hospitalised with confirmed influenza, epidemiological cohort, Influenza 
Complications Alert Network, Australia, April to October 2014 (n=402)
Not admitted to ICU Admitted to ICU Total
Total 356 46 402
Age group
Neonate < 28 days 5 (1.4%) 2 (4.3%) 7 (1.7%)
Infant 28d - 1 year 93 (26.1%) 14 (30.4%) 107 (26.6%)
1–4 years 147 (41.3%) 18 (39.1%) 165 (41.0%)
5–9 years 68 (19.1%) 6 (13.0%) 74 (18.4%)
10–15 years 43 (12.1%) 6 (13.0%) 49 (12.2%)
Smoking 4 (1.1%) 2 (4.3%) 6 (1.5%)
Others smoking in the household 21 (5.9%) 5 (10.9%) 26 (6.5%)
Chronic medical comorbidities 127 (35.7%) 28 (60.9%) 155 (38.6%)
Chronic respiratory disease 38 (10.7%) 12 (26.1%) 50 (12.4%)
Prematurity 33 (9.3%) 12 (26.1%) 45 (11.2%)
Chronic cardiac disease 21 (5.9%) 3 (6.5%) 24 (6.0%)
Diabetes 4 (1.1%) 1 (2.2%) 5 (1.2%)
Chronic neurological disease 26 (7.3%) 7 (15.2%) 33 (8.2%)
Chronic renal disease 10 (2.8%) 4 (8.7%) 14 (3.5%)
Immunosuppressed 35 (9.8%) 4 (8.7%) 39 (9.7%)
Chronic liver disease 7 (2.0%) 3 (6.5%) 10 (2.5%)
Genetic abnormality 28 (7.9%) 10 (21.7%) 38 (9.5%)
Inborn error of metabolism 4 (1.1%) 3 (6.5%) 7 (1.7%)
Chronic aspirin use 4 (1.1%) 0 (0.0%) 4 (1.0%)
Residential care 1 (0.3%) 1 (2.2%) 2 (0.5%)
Influenza vaccination 11/242 (4.5%) 4/35 (11.4%) 15/277 (5.4%)
Influenza subtype
A(H1N1)09pdm 92 (25.8%) 17 (37.0%) 109 (27.1%)
A(H3N2) 24 (6.7%) 8 (17.4%) 32 (8.0%)
A not subtyped 199 (55.9%) 19 (41.3%) 218 (54.2%)
B 40 (11.2%) 2 (4.3%) 42 (10.4%)
multiple strains 1 (0.3%) 0 (0.0%) 1 (0.2%)
Mortality 0/317 (0.0%) 1/41 (2.4%) 1/358 (0.3%)
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Vaccine coverage
Vaccine coverage for all children > 6 months of age, as 
shown in Figure 2, was low. Of the 225 children who 
tested negative for influenza within 7 days of onset of 
illness, 28 children had received at least one dose of 
vaccine in 2014 (estimated full or partial vaccine cover-
age: 12.4%). Eighteen children were regarded as fully 
vaccinated (estimated full coverage: 8.0%) Of those 
with comorbidities (eligible to receive influenza vac-
cine under the NIP), only 16 of 89 children had received 
at least one dose of vaccine in 2014 (estimated full or 
partial coverage: 18.0%), of whom only nine children 
were regarded as fully vaccinated (estimated full cov-
erage: 10.1%).
Vaccine effectiveness
In children aged > 6 months, the crude VE of full or par-
tial vaccination (i.e. children who received at least one 
dose of vaccine in 2014) was estimated as 48.8% (95% 
CI: 1.1–73.5%; Table 4). After adjusting for age group 
and comorbidities, the adjusted full/partial VE was 
estimated as 55.5% (95% CI: 11.6–77.6%). VE differed 
by infecting strain (Table 4) with poor VE against cir-
culating influenza A(H3N2) noted. Only one child with 
A(H1N1) infection was partially vaccinated with no 
vaccine breakthrough cases in fully vaccinated chil-
dren identified: adjusted fully/partial VE estimate for 
A(H1N1) was 91.6% (95% CI: 36.0–98.9%).
In children aged > 6 months, the crude VE based on 
children who were regarded as fully vaccinated in 2014 
was estimated as 30.5% (95%CI -45.7 to 66.8%). After 
adjusting for age group (age < 2 years), and chronic 
medical comorbidities, the adjusted VE was estimated 
as 41.1% (95% CI: -26.7 to 72.6%).
Discussion
Inclusion of two tertiary paediatric hospitals (from 
the separate Paediatric Active Enhanced Disease 
Surveillance network; PAEDS [5]) into the existing 
FluCAN sentinel system has allowed us to report on 
influenza in 3,400 hospitalised children and adults 
in 2014 (unpublished data), inclusive of metropolitan 
and regional hospitals, specialist paediatric and adult 
hospitals and hospitals in tropical and subtropical 
regions. By collecting data on control patients with 
ARI who tested negative for influenza, vaccine cover-
age (particularly in vulnerable patients) and VE against 
severe influenza can also be accurately estimated [20]. 
Here we report the first significant VE estimate against 
hospitalised influenza in Australian children.
In 2014, we recorded over 400 paediatric admissions in 
the FluCAN system. When compared with children with 
influenza requiring hospitalisation in 2009 (n = 601 
across six paediatric hospitals), a number of similari-
ties and differences were identified. In both cohorts, 
more than 50% of children did not have any underly-
ing comorbidities, highlighting that healthy children 
form a significant proportion of those requiring hospi-
tal admission. Indigenous Australians are at increased 
risk of hospital admission with influenza; national hos-
pitalisation discharge data indicate that indigenous 
children aged < 5 years are hospitalised more than 
twice as frequently with influenza compared with their 
non-indigenous peers [21]. This finding has prompted 
the inclusion of Indigenous children < 5 years of age as 
eligible for NIP-funded influenza vaccination from 2015 
onwards. The higher proportion of indigenous children 
enrolled in this study in 2014 (16.0% vs 4.5% in 2009) 
needs to be interpreted with caution as recruitment 
from sites with sizable indigenous populations (e.g. 
Alice Springs Hospital) occurred in 2014 and not in 
2009. The proportion of Indigenous children with influ-
enza in the study (excluding those admitted to Alice 
Springs Hospital) was 6.5% (23/354). This is compared 
with the national average of 4.4% [22].
For all children, similar outcomes were observed in 
2014 compared with 2009, respectively: 11.4% and 
9.9% of children were admitted to ICU, and mortality 
was 0.3% and 0.9% respectively. Despite the avail-
ability of free vaccine through the NIP for children 
with comorbidities from 2010, uptake of seasonal TIV 
in those at greatest risk has not significantly changed 
since 2009: in 2014 only 21.0% of controls with comor-
bidities were vaccinated compared with 18.4% in 2009 
[4]. Another striking difference is the infrequent use of 
antiviral medications in 2014 compared with the pan-
demic year, 2009 (15% vs 47%). The effectiveness of 
Table 3
Factors associated with admission to intensive care in patients hospitalised with confirmed influenza, epidemiological 
cohort, Influenza Complications Alert Network, Australia, April to October 2014 (n=402)
Variable Crude OR (95% CI) p value AOR (95% CI) p value
Infant < 12 months 1.40 (0.73, 2.69) 0.306 1.86 (0.94, 3.69) 0.076
Medical comorbidities 2.80 (1.49, 5.27) 0.001 3.20 (1.66, 6.16) 0.001
Indigenous Australian 0.79 (0.32, 1.94) 0.603 NI NA
Influenza type
Influenza A 1 (referent) 1 (referent)
Influenza B 0.36 (0.08, 1.53) 0.166 NI NA
AOR: adjusted odds ratio; CI: confidence interval; NA: not applicable; NI: not included in final model; OR: odds ratio.
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oseltamivir in children and adults with influenza has 
recently been debated following meta-analyses by 
Jefferson et al. and Dobson et al. with conflicting meth-
ods, results and conclusions [23,24]. Data pooled by 
Jefferson et al. demonstrates that oseltamivir reduces 
the length of symptoms by 29 hours (95% CI: 12 to 47 
hours; p = 0.001) at the expense of increased rates of 
vomiting in children [23]. Despite no appreciable differ-
ence in complications or hospitalisation being noted, 
the numbers of children in both the intervention and 
control arms of these analyses are very small. Given 
the current evidence, oseltamivir is most likely to ben-
efit patients at high risk of hospitalisation and patient 
with influenza requiring hospitalisation [25]. Future 
work should focus on ways to improve both vaccine 
uptake and antiviral use, particularly among children 
with comorbidities or other risk factors for severe 
influenza.
VE estimates are now generated using test-negative 
design in multiple populations to guide vaccine strain 
choice. Existing southern-hemisphere systems and VE 
studies have either focused on children (and adults) 
presenting for outpatient or emergency care [7,26,27] 
or enrolled insufficient numbers of children to gen-
erate robust estimates for hospitalised influenza in 
children, particularly in any single influenza seasons 
[9,26,27]. The addition of large paediatric sites to 
the FluCAN network, has enabled calculation of VE 
estimates against hospitalised influenza for children 
aged < 16 years in a single season. Moreover, the VE 
point estimate (55.5% (95% CI: 11.6–77.6%)) is com-
parable to that observed in hospitalised adults (51.5% 
(95% CI: 41.6–59.7%), unpublished data), albeit with 
less precision. Restricting the estimate to those fully 
vaccinated resulted in a lower point estimate (41.1% 
(95% CI: -26.7–72.6%)) but given the small numbers 
of vaccinated cases and controls and wide confidence 
intervals, this result needs to be interpreted with cau-
tion, Similar differences in VE between different influ-
enza strains were also observed (data not shown). The 
addition of data from more paediatric hospitals, or 
over subsequent seasons, would assist in providing 
VE estimates against specific influenza strains and in 
subgroups of interest, for example the children aged 6 
months to 2 years in whom data on VE is sparse.
There are a number of limitations to this study. The 
decision to test was left to the treating clinician using 
local guidelines. The impact of this is expected to be 
small as influenza tests are routinely recommended 
for infection control purposes in children requiring 
hospital admission with acute respiratory symptoms. 
It remains possible that the decision to test might 
have been influenced by vaccination status. As in all 
observational studies, a biased estimate of VE may 
result from unmeasured confounding or misascertain-
ment of vaccination status or outcome. Case ascertain-
ment was likely incomplete due to the underutilisation 
of influenza laboratory testing by treating clinicians, 
despite the diagnosis of influenza having implications 
for infection control and antiviral use in hospitals. 
Table 4
Estimated vaccine effectiveness against hospitalisation with influenza in children aged > 6 months (vaccine effectiveness 
cohort), Influenza Complications Alert Network, Australia, April to October 2014
Strains
Number of cases and controls
Unadjusted VE (95% 
CI) Adjusted VE








Vaccinated cases inclusive of fully and partially vaccinated children
All 





H1N1 1 72 28 197 90.2% (26.9%, 98.7%)
91.6%c 
(36.0%, 98.9%)
H3N2 13 90 28 197 6.2% (-110.7%, 58.2%)
-4.0% 
(-138.9%, 54.7%)
B 2 22 28 197 66.0% (-163.3%, 95.6%)
65.0% 
(-179.4%, 95.6%)
Vaccinated cases inclusive of fully vaccinated cases only
All 





H1N1 0 72 18 197 100% 100%c
H3N2 11 90 18 197 3.5% (-154.1%, 63.4%)
-13.6% 
(-204.1%, 57.6%)
B 2 22 18 197 47.3% (-317.0%, 93.3%)
51.5% 
(-294.4%, 94.0%)
CI: confidence intervals; VE: vaccine effectiveness.
a adjusted for age > 2 years, and comorbidities
b Inclusive of patients with untyped influenza A infection, H1N1, H3N2 and influenza B.
c 1 patient with A(H1N1) was partially vaccinated and none fully vaccinated. Non-conditional logistic regression used
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Delayed presentations or secondary bacterial pneu-
monia may be associated with false negative influ-
enza tests as the influenza infection may be cleared at 
the time of presentation. Influenza subtyping was not 
available for the majority (55%) of patients, thereby 
limiting our ability to determine the relative burden of 
influenza A types and calculate accurate VE estimates 
by strain. Furthermore, the antigenic characteristics of 
influenza viruses from cases was not performed and as 
such we are unable to determine the relatedness of cir-
culating strains with influenza strains included in the 
2014 seasonal vaccine. The inability to determine vac-
cination status in all children was a limitation although 
no significant differences were noted when influenza 
status and risk factors of those with known vaccination 
status were compared with children with unknown vac-
cination status (data not shown). Low vaccine uptake 
was a major limitation impacting on our ability to more 
precisely calculate VE.
In summary, we describe more than 400 children hos-
pitalised with seasonal influenza in Australia, of whom 
10% required ICU admission. Influenza A was detected 
in 90% of cases with influenza A(H1N109)pdm the 
most frequent subtype. Vaccine uptake in those with 
and without comorbidities remains poor. Use of influ-
enza antivirals in children is infrequent. TIV appeared 
moderately effective against hospitalisation with any 
influenza in 2014, but was more effective against the 
influenza A(H1N109)pdm subtype.
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